About this Research Topic
Gastroesophageal cancer is among the most common malignant diseases worldwide and is associated with high mortality rates, leading to a substantial burden on public health and healthcare systems around the world. Chemotherapeutic drugs have achieved great success in the treatment of esophageal cancer; however, they also bring cytotoxicity to other organs and often have serious side effects. With the development of molecular diagnostics and biomarker discovery, the application of precision medicine has emerged to improve clinical outcomes.
New antineoplastic therapy development is a timely topic in light of the recent development of precision medicine. New biotherapies aim to inhibit or regulate different targets, which are thought to be functionally selective or overexpressed in some types of tumors. In particular, progress has been made to understand the molecular biology of gastrointestinal cancer, resulting in the discovery of various molecular targets, such as KRAS, PD-1, PD-L1, EGFR, HER2 and VEGF. Moreover, anticancer agents, such as pembrolizumab, olaparib, trastuzumab, bevacizumab, either as single agents or in combination with conventional chemotherapy, have become part of the standard of care for treatment of advanced gastroesophageal cancer.
This Research Topic provides a platform for recent studies on novel molecular targets and treatments for gastroesophageal cancer. Both Original Research articles and Reviews are welcome. Subjects may include but are not limited to:
1) Oncogenes and tumor suppressors;
2) Drug sensitivity/resistance;
3) Tumor metastasis and tumor microenvironment;
4) Biomarker discovery and epigenetic regulation.
Keywords: Molecular mechanism, Therapeutic targets, Biomarker discovery, Precision medicine, Gastroesophageal cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.